GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (NAS:SUPN) » Definitions » FCF Yield %

Supernus Pharmaceuticals (Supernus Pharmaceuticals) FCF Yield % : 6.72 (As of Apr. 28, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Supernus Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Supernus Pharmaceuticals's Trailing 12-Month Free Cash Flow is $110.5 Mil, and Market Cap is $1,645.9 Mil. Therefore, Supernus Pharmaceuticals's FCF Yield % for today is 6.72%.

The historical rank and industry rank for Supernus Pharmaceuticals's FCF Yield % or its related term are showing as below:

SUPN' s FCF Yield % Range Over the Past 10 Years
Min: -36.64   Med: 5.06   Max: 16.82
Current: 6.72


During the past 13 years, the highest FCF Yield % of Supernus Pharmaceuticals was 16.82%. The lowest was -36.64%. And the median was 5.06%.

SUPN's FCF Yield % is ranked better than
83.89% of 1080 companies
in the Drug Manufacturers industry
Industry Median: -0.65 vs SUPN: 6.72

Supernus Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 27.38%.


Supernus Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Supernus Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals FCF Yield % Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.37 10.13 8.05 6.02 6.98

Supernus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.70 9.90 -4.64 9.49 11.36

Competitive Comparison of Supernus Pharmaceuticals's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's FCF Yield % falls into.



Supernus Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Supernus Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=110.534 / 1583.695196
=6.98%

Supernus Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=44.994 * 4 / 1583.695196
=11.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Supernus Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Supernus Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Executives
Tami Tillotson Martin officer: Sr. V.P., Regulatory Affairs C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Newhall Charles W Iii director 1119 ST PAUL ST, BALTIMORE MD 21202
Frederick M. Hudson director 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Frank Mottola officer: Sr VP, Quality, GMP Oper. & IT 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Bethany Sensenig director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Jack A. Khattar director, officer: President, CEO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Padmanabh P. Bhatt officer: Sr. VP of IP, CSO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Timothy C Dec officer: Senior Vice-President & CFO C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jonathan Rubin officer: SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Schwabe Stefan K.f. officer: Executive Vice President R&D C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gregory S Patrick officer: VP, Chief Financial Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
James Patrick Kelly officer: Executive Vice-President & CFO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Carrolee Barlow director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Victor Vaughn officer: Sr. VP of Sales C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
M James Barrett director, 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202